Methods of altering bone growth by administration of Sost or Wise antagonist or agonist
AssigneeOssifi-Mab LLC
InventorDebra L. Ellies
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
Claims69
A method for increasing bone formation in a human subject being treated with a sclerostin-recognizing antibody, comprising serially administering an antiresorptive drug alone to the human subject.
A method of treating a human subject being treated with a sclerostin-recognizing antibody to increase bone formation in the human subject, comprising:
- separate administration of a first antiresorptive drug at the same time as the treatment with the sclerostin-recognizing antibody;
- and separate, serial administration of a second antiresorptive drug after the administration of the first antiresorptive drug.
A method for increasing bone formation in a human subject with low bone mineral density being treated with a sclerostin-recognizing antibody and Vitamin D, comprising serial administration of an antiresorptive drug alone to the human subject.
A method for increasing bone mineral density in a human subject with osteoporosis being treated with a sclerostin-recognizing antibody, comprising serially administering an antiresorptive drug alone to the human subject.
A method for increasing bone formation in a human treated with a sclerostin-recognizing antibody and Vitamin D, comprising serial administration of denosumab to the human.
A method for increasing bone mineral density in a human treated with a sclerostin- recognizing antibody and Vitamin D, comprising administering denosumab or alendronate to the human.
Dependencies are inferred from the claim text.